[go: up one dir, main page]

WO2006022954A3 - Benzoureas having anti-diabetic activity - Google Patents

Benzoureas having anti-diabetic activity Download PDF

Info

Publication number
WO2006022954A3
WO2006022954A3 PCT/US2005/018721 US2005018721W WO2006022954A3 WO 2006022954 A3 WO2006022954 A3 WO 2006022954A3 US 2005018721 W US2005018721 W US 2005018721W WO 2006022954 A3 WO2006022954 A3 WO 2006022954A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzoureas
benzourea
diabetes
aryl
diabetic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/018721
Other languages
French (fr)
Other versions
WO2006022954A2 (en
Inventor
Weiguo Liu
Harold B Wood
Fiona Wai-Yu Lau-Phua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to JP2007515386A priority Critical patent/JP2008501027A/en
Priority to US11/597,817 priority patent/US20080076810A1/en
Priority to CA002565803A priority patent/CA2565803A1/en
Priority to EP05812065A priority patent/EP1753423A4/en
Priority to AU2005278099A priority patent/AU2005278099A1/en
Publication of WO2006022954A2 publication Critical patent/WO2006022954A2/en
Publication of WO2006022954A3 publication Critical patent/WO2006022954A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Benzourea compounds of Formula I having aryl-(CH2)x-oxazolidinedione or aryl-(CH2)x-thiazolidinedione substituents on one of the N atoms of the benzourea ring, wherein x is 0 or 1, are PPAR gamma agonists or partial agonists and are useful in the treatment and control of type II diabetes, including hyperglycemia and other symptoms such as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity, that are often associated with type 2 diabetes.
PCT/US2005/018721 2004-05-28 2005-05-26 Benzoureas having anti-diabetic activity Ceased WO2006022954A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007515386A JP2008501027A (en) 2004-05-28 2005-05-26 Benzourea with anti-diabetic activity
US11/597,817 US20080076810A1 (en) 2004-05-28 2005-05-26 Benzoureas Having Anti-Diabetic Activity
CA002565803A CA2565803A1 (en) 2004-05-28 2005-05-26 Benzoureas having anti-diabetic activity
EP05812065A EP1753423A4 (en) 2004-05-28 2005-05-26 BENZO-UREES WITH ANTIDIABETIC ACTIVITY
AU2005278099A AU2005278099A1 (en) 2004-05-28 2005-05-26 Benzoureas having anti-diabetic activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57514404P 2004-05-28 2004-05-28
US60/575,144 2004-05-28

Publications (2)

Publication Number Publication Date
WO2006022954A2 WO2006022954A2 (en) 2006-03-02
WO2006022954A3 true WO2006022954A3 (en) 2006-10-12

Family

ID=35967997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/018721 Ceased WO2006022954A2 (en) 2004-05-28 2005-05-26 Benzoureas having anti-diabetic activity

Country Status (6)

Country Link
EP (1) EP1753423A4 (en)
JP (1) JP2008501027A (en)
CN (1) CN101076334A (en)
AU (1) AU2005278099A1 (en)
CA (1) CA2565803A1 (en)
WO (1) WO2006022954A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006014685A1 (en) * 2006-03-28 2007-10-04 Sanofi-Aventis Imidazo-pyridin-2-one derivatives as inhibitors of lipases and phospholiphases
PT2100604E (en) * 2008-03-10 2012-07-24 Nestec Sa Medium chain dicarboxylic acids and their derivates and metabolic disorders
MX2015003700A (en) * 2012-09-21 2015-10-30 Reoxcyn Discoveries Group Inc Cell for electrolyzing a liquid.
JP7607799B2 (en) * 2021-04-27 2024-12-27 メッドシャイン ディスカバリー インコーポレイテッド Derivatives of six-membered aromatic heterourea rings and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653478B2 (en) * 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO305987B1 (en) * 1994-04-11 1999-08-30 Sankyo Co Heterocyclic compounds with antidiabetic activity, their use and pharmaceutical preparations containing these
CA2495915A1 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653478B2 (en) * 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1753423A4 *

Also Published As

Publication number Publication date
AU2005278099A1 (en) 2006-03-02
CN101076334A (en) 2007-11-21
EP1753423A4 (en) 2009-10-21
WO2006022954A2 (en) 2006-03-02
EP1753423A2 (en) 2007-02-21
JP2008501027A (en) 2008-01-17
CA2565803A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2004019869A3 (en) Indoles having anti-diabetic activity
EP1638947A4 (en) TRIAZOLE DERIVATIVES USEFUL AS INHIBITORS OF 11-BETA HYDROXYSTEROID DESHYDROGENASE-1
JO2397B1 (en) Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1
AU7705601A (en) N-substituted indoles useful in the treatment of diabetes
ATE472531T1 (en) SULFONYL COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE-1
JO2315B1 (en) 11- beta-hydroxysteroid dehydrogenase 1 inhibitors useful the treatment of diabetes obesity and dyslipidemia
NO20035526D0 (en) Compounds for the treatment of metabolic disorders
NI200700200A (en) FUSIONED AROMATIC COMPOUNDS WITH ANTI-DIABETIC ACTIVITY
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
WO2002060434A3 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
NO20015607L (en) Glukagonantagonister / inversagonister
WO2002064094A3 (en) 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
WO2006127503A3 (en) Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1474139A4 (en) INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA
WO2002026729A3 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
CA2499329A1 (en) Indole-3-carboxamides as glucokinase (gk) activators
CY1106757T1 (en) ANTIDIABETIC OXAZODIDINODIONES AND THIAZOLIDINODIONES
WO2006014262A3 (en) Indoles having anti-diabetic activity
WO2006022954A3 (en) Benzoureas having anti-diabetic activity
WO2004037776A3 (en) Novel compounds and their use as prar-modulators
AU2001294673A1 (en) Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
WO2007018956A3 (en) Antidiabetic oxazolidinediones and thiazolidinediones
DE602005024384D1 (en) NEW COMPOUNDS, ITS MANUFACTURE AND USE
ATE515494T1 (en) NEW COMPOUNDS, THEIR PRODUCTION AND USE
DE602005024539D1 (en) NEW COMPOUNDS, ITS MANUFACTURE AND USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2565803

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005278099

Country of ref document: AU

Ref document number: 6718/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11597817

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005812065

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580017194.5

Country of ref document: CN

Ref document number: 2007515386

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005278099

Country of ref document: AU

Date of ref document: 20050526

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005278099

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005812065

Country of ref document: EP